Common driver genes of NSCLC include epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), the proto-oncogene 1 (ROS), receptor tyrosine kinase (ROS1), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MET proto-oncogene, receptor tyrosine kinase (MET) (exon 14 skipping mutation), neurotrophic receptor tyrosine kinase 2 (NTRK), Ret proto-oncogene (RET), etc., which were defined in the National Comprehensive Cancer Network (NCCN) guidelines of NSCLC in 2021. This evidence concerns the gene MARK2 and non-small cell lung carcinoma.